Singleton Kristen D, Serkova Natalie, Beckey Virgina E, Wischmeyer Paul E
Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, CO, USA.
Crit Care Med. 2005 Jun;33(6):1206-13. doi: 10.1097/01.ccm.0000166357.10996.8a.
Heat shock protein (HSP) expression is vital to cellular and tissue protection after stress or injury. However, application of this powerful tool in human disease has been limited, as known enhancers of HSPs are toxic and not clinically relevant. Glutamine (GLN) can enhance HSP expression in non-clinically relevant animal injury models. The aim of this study was to assess the ability of GLN to enhance pulmonary HSP expression, attenuate lung injury, and improve survival after sepsis in the rat.
Prospective, randomized, controlled animal trial.
University research laboratory.
Male Sprague-Dawley rats.
We utilized a rat model of cecal ligation and puncture to induce sepsis. GLN or saline was administered 1 hr after initiation of sepsis via single tail-vein injection. We analyzed heat shock factor-1 phosphorylation, HSP-70, and HSP-25 via Western blot. Tissue metabolism was assayed by magnetic resonance spectroscopy. Occurrence of lung injury was determined via histopathologic examination. An inhibitor of HSP expression, quercetin, was utilized to assess role of HSP expression in prevention of sepsis-related mortality.
GLN, given after initiation of sepsis, enhanced pulmonary heat shock factor-1 phosphorylation, HSP-70, HSP-25, and attenuated lung injury after sepsis. Further, GLN improved indices of lung tissue metabolic function (adenosine 5-triphosphate/adenosine 5-diphosphate ratio, nicotinamide adenine dinucleotide) after sepsis. No significant effect of GLN on lung tissue-reduced glutathione was observed. GLN treatment led to a significant decrease in mortality (33% [6 of 18] GLN-treated rats vs. 78% [14 of 17] saline-treated rats). Administration of the HSP inhibitor quercetin blocked GLN-mediated enhancement of HSP expression and abrogated GLN's survival benefit.
GLN has been safely administered to critically ill patients and shown to improve outcome without clear understanding of the protective mechanism. Our results indicate GLN may prevent the occurrence of lung injury, lung tissue metabolic dysfunction, and mortality after sepsis via enhancement of deficient lung heat shock factor-1 phosphorylation/activation and HSP expression.
热休克蛋白(HSP)表达对应激或损伤后的细胞和组织保护至关重要。然而,由于已知的热休克蛋白增强剂具有毒性且与临床无关,这一强大工具在人类疾病中的应用受到限制。谷氨酰胺(GLN)可在非临床相关的动物损伤模型中增强热休克蛋白表达。本研究旨在评估谷氨酰胺增强大鼠脓毒症后肺组织热休克蛋白表达、减轻肺损伤及提高生存率的能力。
前瞻性、随机、对照动物试验。
大学研究实验室。
雄性Sprague-Dawley大鼠。
我们采用盲肠结扎穿孔大鼠模型诱导脓毒症。脓毒症开始后1小时,通过单尾静脉注射给予谷氨酰胺或生理盐水。通过蛋白质免疫印迹法分析热休克因子-1磷酸化、热休克蛋白-70和热休克蛋白-25。通过磁共振波谱法检测组织代谢。通过组织病理学检查确定肺损伤的发生情况。使用热休克蛋白表达抑制剂槲皮素评估热休克蛋白表达在预防脓毒症相关死亡中的作用。
脓毒症开始后给予谷氨酰胺可增强肺组织热休克因子-1磷酸化、热休克蛋白-70、热休克蛋白-25表达,并减轻脓毒症后的肺损伤。此外,谷氨酰胺可改善脓毒症后肺组织代谢功能指标(三磷酸腺苷/二磷酸腺苷比值、烟酰胺腺嘌呤二核苷酸)。未观察到谷氨酰胺对肺组织还原型谷胱甘肽有显著影响。谷氨酰胺治疗导致死亡率显著降低(谷氨酰胺治疗组18只中有6只,占33%;生理盐水治疗组17只中有14只,占78%)。给予热休克蛋白抑制剂槲皮素可阻断谷氨酰胺介导的热休克蛋白表达增强,并消除谷氨酰胺的生存获益。
谷氨酰胺已被安全地应用于危重症患者,并显示可改善预后,但目前尚不清楚其保护机制。我们的结果表明,谷氨酰胺可能通过增强肺组织中缺乏的热休克因子-1磷酸化/激活及热休克蛋白表达,预防脓毒症后肺损伤、肺组织代谢功能障碍及死亡的发生。